Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBL-015 in Advanced Malignant Tumors
NCT05107011Phase 2Completed
- Sponsor
- Leads Biolabs
- Start
- Nov 2021
- Primary completion
- Dec 2023
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of LBL-015 in advanced malignant solid tumor, sponsored by Leads Biolabs. Primary endpoints: Maximum tolerated dose at 28 days and Dose-limiting toxicities at 28 days. Started Nov 2021; status: completed.
02
Drugs
LBL-015
03
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT05107011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05107011.